Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 769 posts found.

AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment

November 13, 2023
Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer

AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …

News

AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment

November 6, 2023
Research and Development AstraZeneca, CKD, Nephrology, kidney disease, proteinuria

AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the …

News

AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development

November 1, 2023
Research and Development AstraZeneca, CGT, Pharmacy, cell therapy, cellectis, genomic medicine

AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next generation cell and gene therapeutics …

News

AstraZeneca’s sBLA for FluMist Quadrivalent accepted by FDA

October 24, 2023
Medical Communications AstraZeneca, FDA, FluMist, Immunology, flu vaccine, sBLA

AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics License Agreement …

News

AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC

October 23, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology

AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …

News

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …

News

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

September 11, 2023
Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …

News

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

September 4, 2023
Medical Communications AstraZeneca, CLL, China, Oncology, SLL

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …

News
towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

Japan approves AstraZeneca’s Soliris for paediatric patients with gMG

August 24, 2023
Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris

AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use …

News

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

August 18, 2023
Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …

News
genes

AstraZeneca’s Alexion partners with Pfizer for rare disease therapies

July 28, 2023
Research and Development Alexion, AstraZeneca, Pfizer, Rare Diseases, genomics, rare disease

Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and licence agreement with Pfizer. The …

News
1200px-vaccine_image_1_1

FDA approves AstraZeneca’s drug to prevent RSV in babies and young children

July 18, 2023
Research and Development AstraZeneca, FDA, Immunology, RSV, Vaccine, paediatrics

The US Food and Drug Administration (FDA) has announced that it has approved Beyfortus (nirsevimab-alip) for the prevention of respiratory …

News
lungs

AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC

July 3, 2023
Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …

News
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes

June 27, 2023
Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes

AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has now been approved …

News

AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation

June 26, 2023
Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris

UK-based biopharmaceutical company AstraZeneca has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024